A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases

Trial Profile

A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 May 2017

At a glance

  • Drugs Memantine (Primary)
  • Indications Brain metastases; Cognition disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2017 Planned primary completion date changed from 1 Nov 2020 to 1 Sep 2018.
    • 25 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 19 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top